Smarter™ Sonogenetic CAR-T Development Service harnesses ultrasound-responsive genetic switches to achieve noninvasive, spatiotemporal control of CAR-T activation, enhancing safety, precision, and therapeutic tunability in solid tumor treatment.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Chemically induced dimerization (CID) is a biological system used to study protein interactions and signal transduction pathways. In CID systems, individual protein units are engineered to contain specific domains that will only interact and form a functional protein complex when exposed to a certain chemical or drug. This ability to control the assembly and activity of a protein complex gives researchers precise control over cellular processes. At Creative Biolabs, we utilize a CID system to control the expression of the cytokine receptor in CAR-T therapies. This method could potentially be a more efficient and safer method of CAR-T cell activation.
In the context of T cells, a cytokine receptor can be used as the third signal for activation. The CID-cytokine receptor chimera enables the precise control of cytokine receptor expression to regulate immune responses. It helps in controlling associated immunotherapeutic treatments with CAR-T cells. The dimerization event should also be reversible so that the activation of the T cells can be tightly controlled.
The CID-cytokine receptor chimera approach is advantageous as it allows for better control over CAR-T cell therapies by offering an external 'switch' to modulate therapy activity. At Creative Biolabs, we offer the design and construction services of CID-cytokine receptor chimera. Our team of experts works closely to develop a custom CID-cytokine receptor chimera, which utilizes the CID system to control the expression of the cytokine receptor, serving as the third signal for T cell activation.
A CID-cytokine receptor chimera typically consists of three main components: a CID domain, a transmembrane domain, and an intracellular domain of cytokine receptor. Our service includes the construction of a CID-cytokine receptor chimera featuring your desired cytokine receptor. The construction of this chimera involves cloning the gene of the cytokine receptor of your interest into a vector containing a CID system.
| CID System | Dimerizing agent | Cytokine Receptor |
| FKBP-FRB | Rapamycin/analog | IL2R, IL7R, IL12R, IL15R, IL21R |
| FKBP–FKBP | FK1012 | |
| FKBP-Calcineurin A (CNA) | FK506 | |
| ABI-PYRMandi | Mandipropamid | |
| GID1–GAI | Gibberellin | |
| SNAP-tag | HaXS |
Successfully developing a novel CID-cytokine receptor chimera requires a robust pipeline encompassing advanced molecular design through functional cell-based testing. We leverage the following core technology platforms to ensure construct fidelity and functional efficacy:
Upon project completion, clients receive the final plasmid/viral vector construct, a comprehensive QC report, and in vitro functional validation data. Contact our team to arrange a private consultation and receive a comprehensive technical plan.
What's the primary advantage of CID-Cytokine Receptor Chimera over simple suicide genes?
Unlike irreversible suicide genes causing permanent cell loss, CID chimeras offer reversible, tunable control over T-cell function/proliferation for activity fine-tuning and toxicity reduction without eliminating therapeutic cells.
Which cytokine receptors are commonly integrated into chimeras, and why?
Domains from IL-7R, IL-12R, or IL-15R are frequent. These provide "signal 3" for T-cell proliferation/survival, and CID control ensures expansion only with ligand, preventing uncontrolled growth.
What precautions for dimerizing agent use in preclinical settings?
Ensure ligand concentration achieves desired dimerization without off-target effects. Our service includes dose-response studies to define the therapeutic window for precise chimera regulation.
Contact us to arrange a private briefing and obtain a specialized technical proposal.
Smarter™ Sonogenetic CAR-T Development Service harnesses ultrasound-responsive genetic switches to achieve noninvasive, spatiotemporal control of CAR-T activation, enhancing safety, precision, and therapeutic tunability in solid tumor treatment.
TCR-controlled Fuzzy Logic CAR Construction Service integrates TCR signaling logic into CAR design, enabling context-dependent activation that distinguishes malignant from healthy cells, improving selectivity and minimizing off-target toxicity.
Chimeric cytokine receptors are genetically engineered fusion proteins that can specifically activate or inhibit intracellular signaling pathways. At Creative Biolabs, our experts offer reliable solutions to help you engineer T cells to express a chimeric cytokine receptor that is activated via a CID system. We have a team of experienced scientists and cutting-edge technology to ensure high-quality construct development tailored to the research needs of our clients. We also offer thorough testing to verify the functionality of the chimera, including its ability to properly stimulate CAR-T cell activation.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
